Satellos Bioscience (TSE:MSCL) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Satellos Bioscience Inc. has reached a critical milestone by submitting a proposal to conduct a Phase 1 clinical trial for its new drug SAT-3247, aimed at treating muscle diseases. The trial is set to begin in the third quarter of 2024, signaling the company’s transition to a clinical-stage entity. SAT-3247, an oral small molecule drug, shows promise in regenerating skeletal muscle affected by conditions like Duchenne muscular dystrophy.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
